Pulse Biosciences, Inc. (PLSE)
- Previous Close
16.85 - Open
16.78 - Bid 12.09 x 200
- Ask 22.38 x 200
- Day's Range
16.78 - 16.79 - 52 Week Range
6.66 - 25.00 - Volume
2,489 - Avg. Volume
183,635 - Market Cap (intraday)
1.13B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.92 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
www.pulsebiosciences.comRecent News: PLSE
View More
Performance Overview: PLSE
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLSE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLSE
View MoreValuation Measures
Market Cap
1.13B
Enterprise Value
1.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.70%
Return on Equity (ttm)
-67.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-53.59M
Diluted EPS (ttm)
-0.92
Balance Sheet and Cash Flow
Total Cash (mrq)
118.04M
Total Debt/Equity (mrq)
7.75%
Levered Free Cash Flow (ttm)
-17.92M
Research Analysis: PLSE
View MoreResearch Reports: PLSE
View MoreDaily – Vickers Top Buyers & Sellers for 12/18/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 02/16/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/15/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 02/14/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.